JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma

Leukemia

Volumn 28, Issue 2, 2014, Pages 338-348

  Bouchekioua, A ^a,b,c   Scourzic, L ^b   De Wever, O ^d   Zhang, Y ^a,b   Cervera, P ^e   Aline Fardin, A ^e   Mercher, T ^b   Gaulard, P ^f,g,h   Nyga, R ⁱ   Jeziorowska, D ^c   Douay, L ^c   Vainchenker, W ^a,b   Louache, F ^a,b   Gespach, C ^j   Solary, E ^a,b   Coppo, P ^a,e  

^a UNIVERSITÉ PARIS EST   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e SORBONNE UNIVERSITÉ   (France)

^f INSERM U955   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ EA 4559   (France)

^j CENTRE DE RECHERCHE SAINT ANTOINE   (France)

more..

Author keywords

JAK3; leukemia; natural killer lymphoma; STAT3

Indexed keywords

5 FLUORO 2 [[1 (4 FLUOROPHENYL)ETHYL]AMINO] 6 [(5 METHYL 1H PYRAZOL 3 YL)AMINO] 3 PYRIDINECARBONITRILE; ANTIBODY; COLLAGEN TYPE 1; LIPOCORTIN 5; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHOPROTEIN; PROPIDIUM IODIDE; PROTEIN KINASE TYK2; SMALL INTERFERING RNA; STAT3 PROTEIN; TOFACITINIB; TYROSINE; TYROSINE 980; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DEREGULATION; DISEASE COURSE; DISSEMINATED CANCER; DNA SEQUENCE; DRUG ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYMPH NODE BIOPSY; MALE; MALIGNANT TRANSFORMATION; MAP KINASE ASSAY; MIDDLE AGED; MOUSE; NASAL BIOPSY; NK T CELL LYMPHOMA; NONHUMAN; ORAL BIOPSY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR INVASION; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 3; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MICE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PHOSPHORYLATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893761035     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.157     Document Type: Article

References (41)

1. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol 2003; 40: 175-184.
2. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008; 112: 4384-4399.
3. Kanavaros P, Lescs MC, Briere J, Divine M, Galateau F, Joab I et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993; 81: 2688-2695.
4. Kim TM, Lee SY, Jeon YK, Ryoo BY, Cho GJ, Hong YS et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 2008; 19: 1477-1484.
5. Nagafuji K, Fujisaki T, Arima F, Ohshima K. L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001; 74: 447-450.
6. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011; 117: 1834-1839.
7. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011; 29: 4410-4416.
8. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113: 3931-3937.
9. Coppo P, Gouilleux-Gruart V, Huang Y, Bouhlal H, Bouamar H, Bouchet S et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasaltype NK/T-cell lymphoma. Leukemia 2009; 23: 1667-1678.
10. Huang Y, de Reynies A, de Leval L, Ghazi B, Martin-Garcia N, Travert M et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 2010; 115: 1226-1237.
11. Iqbal J, Weisenburger DD, Chowdhury A, Tsai MY, Srivastava G, Greiner TC et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gamma delta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia 2011; 25: 348-358.
12. Karube K, Nakagawa M, Tsuzuki S, Takeuchi I, Honma K, Nakashima Y et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 2011; 118: 3195-3204.
13. Kucuk C, Iqbal J, Hu X, Gaulard P, De Leval L, Srivastava G et al. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci USA 2011; 108: 20119-20124.
14. Quintanilla-Martinez L, Kremer M, Keller G, Nathrath M, Gamboa-Dominguez A, Meneses A et al. p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. Am J Pathol 2001; 159: 2095-2105.
15. Takakuwa T, Dong Z, Nakatsuka S, Kojya S, Harabuchi Y, Yang WI et al. Frequent mutations of Fas gene in nasal NK/T cell lymphoma. Oncogene 2002; 21: 4702-4705.
16. Takahara M, Kishibe K, Bandoh N, Nonaka S, Harabuchi Y. P53, N-and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. Hum Pathol 2004; 35: 86-95.
17. Jeon YK, Kim H, Park SO, Choi HY, Kim YA, Park SS et al. Resistance to Fas-mediated apoptosis is restored by cycloheximide through the downregulation of cellular FLIPL in NK/T-cell lymphoma. Lab Invest 2005; 85: 874-884.
18. Ng SB, Yan J, Huang G, Selvarajan V, Tay JL, Lin B et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood 2011; 118: 4919-4929.
19. Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995; 76: 2351-2356.
20. Bossard C, Belhadj K, Reyes F, Martin-Garcia N, Berger F, Kummer JA et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2007; 109: 2183-2189.
21. Malamut G, El Machhour R, Montcuquet N, Martin-Lanneree S, Dusanter-Fourt I, Verkarre V et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest 2011; 120: 2131-2143.
22. Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma. Leukemia 2000; 14: 777-782.
23. De Wever O, Hendrix A, De Boeck A, Westbroek W, Braems G, Emami S et al. Modeling and quantification of cancer cell invasion through collagen type I matrices. Int J Dev Biol 2010; 54: 887-896.
24. Ju W, Zhang M, Jiang JK, Thomas CJ, Oh U, Bryant BR et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 2011; 117: 1938-1946.
25. Gozgit JM, Bebernitz G, Patil P, Ye M, Parmentier J, Wu J et al. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem 2008; 283: 32334-32343.
26. Kim TM, Heo DS. Extranodal NK/T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci 2009; 100: 2242-2248.
27. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006; 10: 65-75.
28. Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C et al. Activating mutations in human acute megakaryoblastic leukemia. Blood 2008; 112: 4220-4226.
29. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507.
30. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-519.
31. Knoops L, Renauld JC. IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors 2004; 22: 207-215.
32. Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC. JAK kinases overexpression promotes in vitro cell transformation. Oncogene 2008; 27: 1511-1519.
33. Cornejo MG, Boggon TJ, Mercher T. JAK3: a two-faced player in hematological disorders. Int J Biochem Cell Biol 2009; 41: 2376-2379.
34. Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood 2009; 113: 2746-2754.
35. Crockett DK, Lin Z, Elenitoba-Johnson KS, Lim MS. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 2004; 23: 2617-2629.
36. Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Dave UP. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011; 118: 3911-3921.
37. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163.
38. Yu JB, Zhang YC, Yang QP, Wang XL, Tang Y, Zhao S et al. Invasion-associated genes identified by gene expression profiling in extranodal natural killer/T-cell lymphoma, nasal type. Leuk Lymphoma 2012; 54: 90-98.
39. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011; 147: 992-1009.
40. Carragher NO, Walker SM, Scott Carragher LA, Harris F, Sawyer TK, Brunton VG et al. Calpain 2 and Src dependence distinguishes mesenchymal and amoeboid modes of tumour cell invasion: a link to integrin function. Oncogene 2006; 25: 5726-5740.
41. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L et al. Janus Kinase 3-Activating Mutations Identified in Natural Killer/T-cell Lymphoma. Cancer Discov 2012; 2: 591-597.